Medpace price target raised to $480 from $452 at UBS

UBS raised the firm’s price target on Medpace to $480 from $452 and keeps a Buy rating on the shares. The firm came away from meetings with Medpace’s management increasingly confident that 2024 guidance is achievable and that there is upside to 2025 consensus if the funding recovery were to continue, the analyst tells investors in a research note.